Is Ariad Pharmaceuticals, Inc. a Sell? The Stock Had Bearish Options Activity Today

 Is Ariad Pharmaceuticals, Inc. a Sell? The Stock Had Bearish Options Activity Today

In today’s session Ariad Pharmaceuticals, Inc. (ARIA) recorded an unusually high (2,203) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious ARIA decrease. With 2,203 contracts traded and 26524 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: ARIA161118P00013000 closed last at: $0.6 or 47.8% down. About 247,426 shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 94.40% since April 14, 2016 and is uptrending. It has outperformed by 89.72% the S&P500.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage

Out of 7 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 3 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 43% are positive. $22 is the highest target while $5 is the lowest. The $13.19 average target is 1.54% above today’s ($12.99) stock price. Ariad Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Underweight” rating by Barclays Capital on Wednesday, May 11. On Monday, October 24 the stock rating was downgraded by JP Morgan to “Underweight”. The firm earned “Buy” rating on Wednesday, October 5 by Suntrust Robinson. JP Morgan maintained Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rating on Friday, August 7. JP Morgan has “Neutral” rating and $9 price target. The firm earned “Underweight” rating on Tuesday, January 19 by Barclays Capital. JMP Securities downgraded Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Tuesday, October 25 to “Mkt Perform” rating. The rating was initiated by Leerink Swann on Monday, September 26 with “Outperform”. Barclays Capital maintained Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rating on Friday, July 29. Barclays Capital has “Underweight” rating and $9 price target. As per Thursday, November 3, the company rating was initiated by Deutsche Bank. JMP Securities maintained it with “Market Outperform” rating and $9 target price in Wednesday, March 9 report.

According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”

Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.73, from 0.67 in 2016Q1. The ratio is positive, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Canada Pension Plan Inv Board, a Ontario – Canada-based fund reported 20,900 shares. Numeric Limited Liability Corporation accumulated 87,600 shares or 0.01% of the stock. Financial Architects, a New Jersey-based fund reported 500 shares. Fmr Limited Liability Corporation last reported 0.01% of its portfolio in the stock. The Illinois-based Nuveen Asset has invested 0% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Tru Of Vermont owns 650 shares or 0% of their US portfolio. Millennium Ltd Liability Corp reported 256,117 shares or 0% of all its holdings. Mackenzie Corporation holds 0% or 113,737 shares in its portfolio. Moreover, Opaleye Mngmt has 0.95% invested in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 340,000 shares. Goldman Sachs Group has invested 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Citadel Advsr Limited Liability owns 78,711 shares or 0% of their US portfolio. Moreover, Parallax Volatility Advisers Lp has 0% invested in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 337,689 shares. Allianz Asset Mgmt Ag owns 148,721 shares or 0% of their US portfolio. Cornerstone Cap Mngmt Holdings Ltd Company reported 35,517 shares or 0% of all its holdings. Los Angeles Capital Mgmt & Equity Research Incorporated has 0% invested in the company for 14,545 shares.

Insider Transactions: Since May 23, 2016, the stock had 0 insider purchases, and 11 insider sales for $4.01 million net activity. On Friday, August 12 CLACKSON TIMOTHY P sold $262,500 worth of the stock or 25,000 shares. LAVIDAS ATHANESE also sold $626,039 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares. 108,569 shares were sold by Radaelli Massimo, worth $896,135.

ARIAD Pharmaceuticals, Inc. is an oncology company. The company has a market cap of $2.51 billion. The Firm is focused on transforming the lives of cancer patients with medicines. It currently has negative earnings. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.

ARIA Company Profile

ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.

More news for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) were recently published by: Fool.com, which released: “3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results” on November 07, 2016. Seekingalpha.com‘s article titled: “Brigatinib Will Create Transformative Growth For Ariad” and published on November 15, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment